Combination products: adapting the EU regulatory framework to reality
This article was originally published in SRA
Executive Summary
Shayesteh Fürst-Ladani says that EU rules on combination healthcare products must avoid duplication of evidence gathering and of regulatory submissions and provide opportunities for early dialogue between stakeholders.